Perspective Announces Positive Phase 1/2a Trial Results for 212Pb-Bamzireotide
The company reported robust tumor responses and durable disease control in a study of [212Pb]VMT-alpha-NET for neuroendocrine tumors, aiming to begin Phase 3 trials in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed